Background data for: Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomydoi:10.18710/T5BQ22DataverseNO2026-04-131Konst, Solveig; Brun, Vegard; Hellemo, Lars, 2026, "Background data for: Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomy", https://doi.org/10.18710/T5BQ22, DataverseNO, V1Background data for: Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomydoi:10.18710/T5BQ22Konst, SolveigBrun, VegardHellemo, LarsKaut, MichalEriksen, BrunSelseth, RuthJohansson, KenthVik, RenateDavidsen, BenedicteUiT The Arctic University of Norway357035HN1004-17DataverseNOUiT The Arctic University of NorwayBrun, VegardKonst, Solveig Robertsen2026-02-23Medicine, Health and Life SciencesThyroidectomyPatient-centered medicineLevothyroxineHypothyroidismPharmacokinetic modeling<p>This dataset constitutes the background data for the study: Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomy (doi: 10.1089/thy.2021.0125). The study's objective was to investigate whether a new pharmacokinetic/pharmacodynamic model for Levothyroxine dosage lead to better and faster levothyroxine dosage. Patients >18 years with a planned total thyroidectomy were eligible for participation.</p> <p>Data were collected in two phases. The first phase, conducted from 2016 to 2017, comprised the pilot study. Data from the pilot study was used to develop the pharmacokinetic/pharmacodynamic model.</p> <p>The second phase, conducted from 2017 to 2019, consisted of a randomised controlled trial utilizing the Pharmacokinetic/pharmacodynamic model for calculating each patient's optimal levothyroxine dosage.</p> <p>Data collected in the two phases are patient demographics, laboratory results and levothyroxine dosage. Laboratory results and levothyroxine dosage were collected at multiple time points during the study, both before and after surgery. Data from the pilot study and the RCT have been merged and anonymised.</p> <p>All participants provided written informed consent for data collection.</p>20162019NorwaySwedenClinical dataData were collected directly from patients or from patients’ electronic health records. Anonymized data are reproduced here in accordance with approval by the Norwegian Regional Ethics Committee (2016/1782) and the Swedish Ethical Review Authority (443-17).<a href="http://creativecommons.org/publicdomain/zero/1.0">CC0 1.0</a>Brun VH, Eriksen AH, Selseth R, Johansson K, Vik R, Davidsen B, Kaut M, Hellemo L. Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomy. Thyroid. 2021 Sep;31(9):1297-1304. doi: 10.1089/thy.2021.0125. Epub 2021 Jun 22. PMID: 33980057; PMCID: PMC8558060.10.1089/thy.2021.0125Brun VH, Eriksen AH, Selseth R, Johansson K, Vik R, Davidsen B, Kaut M, Hellemo L. Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomy. Thyroid. 2021 Sep;31(9):1297-1304. doi: 10.1089/thy.2021.0125. Epub 2021 Jun 22. PMID: 33980057; PMCID: PMC8558060.00-readme.txttext/plainconsent-form.pdfapplication/pdfdata-privacy-assessment.pdfBrief summary of the legal and ethical justification for publishing this dataset with open access.application/pdfLab-results.txttext/plainLevothyroxine-Dosage.txttext/plainPatient-demographic.txttext/plainThyrogen-Dosage.txttext/plain